Clin Osteol 2003; 8(1): 14-17

Calcimimetics - perspective agents in the treatment of hyperparathyroidismArticles

©. Kutílek, M. Bayer

Extracellular calcium ion concentration is the major determinant of parathyroid hormone (PTH) secretion from parathyroid cells. This mechanism is regulated through a 120 kDa calcium sensing receptor (CaSR). In hyperparathyroidism (HPT), excessive PTH is secreted and calcium sensitivity of the cells is reduced due to decreased expression of CaSR. Modulation of the sensitivity of parathyroid cells to calcium is possible through the use of calci­ mimetics. Calcimimetics are small organic molecules that activate CaSR and thus inhibit PTH secretion. Two mechanistically distinct classes of calci­ mimetics have been identified: type I which are full agonists of the CaSR and include polyvalent cations, and type II which are positive allosteric acti­ vators. Calcimimetics are capable of decreasing PTH secretion in pr successfully performed.

Keywords: parathyroid hormone, hyperparathyroidism, calcimimetics

Published: June 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutílek ©, Bayer M. Calcimimetics - perspective agents in the treatment of hyperparathyroidism. Osteologický bulletin. 2003;8(1):14-17.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brown EM. The p Res 2002;17:24-29. Go to original source...
    2. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an cellular Ca(2+) sensing receptor from bovine parathyroid. Nature 1993;366: 575-580. Go to original source...
    3. Brown EM, MacLeod RJ. Extracellular signaling. Physiol Rev 2001;81:239-297. Go to original source...
    4. Conigrave AD, Franks AH, Brown EM et al. L-Aminoacid sensing by the calciumsensing receptor: a general mechanism fo lism? Eur J Clin Nutr 2002;56:1072-1080. Go to original source...
    5. Kifor O, Kifor I, Brown E. Signal transduction in the parathyroid. Curr Opi hrol Hypertens 2002;11:397-402. Go to original source...
    6. Thakker RV. Disorders of the calcium-sensing receptor. Biochem Biophys Acta 1998;1448:166-170. Go to original source...
    7. D'Souza-Li L, Yang B, Canaff L et al. Identification and functional characteri ton of novel calcium-sensing receptor mutations in familial hypocalciuric hyper­ calcemia and autosomal dominant hypocalcemia. J Clin Endocrinol Metab 2002; 87:1309-1318. Go to original source...
    8. Marx SJ, Simonds WF, Agarawal SK et al. Hyperparathyroidism in hereditary syndromes: Special expressions and special managements. J Bone Miner Res 2002;17:37-43.
    9. Curley AJ, Harding B, Bowl MR et a. An activating calcium sensing receptor mu­ tation associated with normocalcemic (idiopathic) hypercalciuric nephrolithiasis. J Bone Miner Res 2002;17,Suppl 1:127:1008
    10. Akizawa T, Fukagawa M. Modulation of parathyroid cell function by calcium ion in health and uremia Am J Med Sci 1999;317:358-362. Go to original source...
    11. Silver J. Molecular mechanism of secondary hyperparathyroidism. Nephrol Dial Transplant 2000;15:Suppl 5:2-7. Go to original source...
    12. Drueke TB. The place of calcium nad calcimimetics in the treatment of sec ry hyperparathyroidism. Nephrol Dial Transplant 2000;16:Suppl 6:15-17. Go to original source...
    13. Goodman WF. Calcimimetic agents and secondary hyperparathyroidism: treat­ ment and prevention. Nephrol Dial Transplant 2002;17:204-207. Go to original source...
    14. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent an lective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-4045. Go to original source...
    15. Nemeth EF, Delmar EG, Heaton WL et al. Calcilytic compounds: potent and se­ lective Ca2+ receptor antagonists th Pharmacol Exp Ther 2001;299:323-331. Go to original source...
    16. Nemeth EF. Pharmacologi Pharm Des 2002;8:2077-2087.
    17. Miedlich S, Gama L, Breitweiser GE. Calcium sensing receptor activation by a calcimimetic suggests a link between coope cillations. J Biol Chem 2002;277:49691^9699. Go to original source...
    18. Schomig M, Ritz E. Management of disturbed calcium metabolism in uraemic pa­ tients: 3. Pot Suppl 5:30-31.
    19. Zhang Z, Jiang Y, Quinn SJ et al. L-phenylalanine and NPS R-467 synergistically potentiate the function of the extracellular calcium-sensing receptor through stinct sites. J Biol Chem 2002;277?33734-33741. Go to original source...
    20. Fox J, Lowe SH, Conklin RL et al. Calcimimetic compound NPS R-568 stimula­ tes calcitonin secretion but selectively targets parathyroid gland Ca(2+) recep in rats. J Pharmacol Exp Ther 1999;290:480-486. Go to original source...
    21. Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decrea­ ses plasma PTH in rats with mild and severe renal or dietary secondary hyperpa­ rathyroidism. Endocrine 1999;10:97-103. Go to original source...
    22. Chin J, Miller SC, Wada M et al. Activation of the calcium receptor by a c metic compound halts the progression of secondary hyperparathyroidism in ure­ mic rats. J Am Soc Nephrol 2000;11:903-911. Go to original source...
    23. Wada M, Nagano N, Furuya Y et al. Calcimimetic NPS R-568 prevents parathy­ roid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57:50-58. Go to original source...
    24. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 supresses parathyroid cell proliferation in rats with renal insufficiency. Contro parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100:2977-2983. Go to original source...
    25. Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000;26:175-182. Go to original source...
    26. Wada M, Ishii H, Furuya Y et al. NP uremic rats. Kidney Int 1998;53:448^53. Go to original source...
    27. Miler MA, Fox J. Daily transient decreases in plasma parathyroid hormone l induced by the calcimimetic NPS R-568 slows the rate of bone loss but doea not increase bone mass in ovariectomized mice. Bone 2000;27:511-519. Go to original source...
    28. Cohen A, Silverberg SJ. Calcimimetics: therapeutic potential in hyperparathy dism. Curr Opin Pharmacol 2002;2:734-739. Go to original source...
    29. Antoniucci DM, Shoback D. Calcimimetics in the treatment of primary hyperpa­ rathyroidism. J Bone Miner Res 2002;17:141-145.
    30. Brancaccio D, Cozzlino M, Gorio A et al. Bone disease in uremic patients: ad ces in PTH suppression. J Nephrol 2002;15:86-93.
    31. Goodman WG, Turner SA Future role of calcimimetics in end-stage disease. Adv Ren Replace Ther 2002;9:200-208. Go to original source...
    32. Silverberg SJ, Bone HG 3rd, Marriot TB et al. Short-term inhibition of parath id hormone secretion by a calcium-receptor agonist in patients with primary hy­ perparathyroidism. N Engl J Med 1997;337:1506-1510. Go to original source...
    33. Lalonde RL, Gaudreault J, Karhu DA et al. Mixed-effects modeling of the phar­ macodynamic response to the calcimimetic agent R-568. Clin Pharmcol Ther 1999;65:40 49. Go to original source...
    34. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic real failure. Rapid communi­ cation. Kidney Int 1998;53:223-227. Go to original source...
    35. Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plas­ ma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-445. Go to original source...
    36. Collins MT, Skarutis MC, Bilezikian JP et al. Treatment of hypercalcemia sec dary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1080-1083. Go to original source...
    37. Nemeth EF. How to control parathyroid hormone secretion. J Bone Miner Res 2002;17:Suppl 1:58(State-of-art lecture).
    38. Shoback DM, Bilezikian J, Binder TA et al. Calcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism. J Bone Miner Res 2000;15:Suppl 1:210.
    39. Shoback DM, Firek AF, Mims RB et al. An evaluation of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism. J Bone Mi­ ner Res 2001;16:Suppl 1:303.
    40. Peacock M, Shoback DM, Greth WE et al. The calcimimetic AMG 073 reduces serum calcium in patients with primary hyperparathyroidism. J Bone Miner Res 2001;16:Suppl 1:163.
    41. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lo­ wers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-1024. Go to original source...
    42. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroi­ dism. Kidney Int 2003;63:248-254. Go to original source...
    43. Frazao JM, Martins P, Coburn JW. The calcimimetic agents: perspectives for t atment. Kidney Int Suppl 2002;80:149-154. Go to original source...
    44. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol 2001;2:347-354. Go to original source...
    45. Weigel RJ. Nonoperative management of hyperparathyroidism: present and futu­ re. Curr Opin Oncol 2001;13:33-38. Go to original source...
    46. Neer RM, Araud CD, Zanchetta JR et al. Effect ofparathyroid hormone (1-34) fractures and bone mineral density in postmenopausal osteoporosis. N Eng J Med 2001;344:1434-1441. Go to original source...
    47. Cinacalcet: AMG 073, Calcimimetics - Amgen/NPS Pharmaceuticals. Drugs RD 2003;4:39-41. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.